The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome

Harper, Ashton; Naghibi, Malwina; Garcha, Davinder

doi:10.3390/foods7020013

Cited by 69 publications

(41 citation statements)

References 125 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, a careful history may reveal patterns of symptoms linked to specific food consumption. Although debatable, a high-fiber diet has traditionally been encouraged particularly in IBS-C patients, given the absence of serious side effects and its potential benefit [88,89]. In recent years, there has been a growing clinical and scientific interest in the use of a diet low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) in IBS patients.…”

Section: Dietary Interventionmentioning

confidence: 99%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

The intestinal microbiota is one of the most rapidly evolving areas in biology and medicine. Extensive research in the last decade has escalated our understanding of the role of the microbiota in the pathogenesis of several intestinal and extra-intestinal disorders. Marked by high prevalence, substantial morbidity, and enormous costs, irritable bowel syndrome (IBS) is an important chronic gastrointestinal disorder that is widely encountered by gastroenterologists. Despite advances in our understanding of its pathophysiology, curative interventions have yet to be discovered, and therapeutic approaches remain symptom-driven. Recently, accumulating evidence has enlightened the possible impact of an imbalanced gut microbiome in the pathogenesis of IBS. In fact, several studies have documented altered microbiota in patients, while others have shown that IBS severity was associated with a distinct microbiota signature. These findings may pave the way for the use of microbiota manipulation strategies as an attractive option for IBS management, and may have an essential role in efforts to reduce the societal and economic effects of this ever-growing disorder. In this review, we have outlined the results of the latest research on the association between microbiota and IBS and their implications for the clinical management of affected patients.

show abstract

Section: Dietary Interventionmentioning

confidence: 99%

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Mari

Baker

Mahamid

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…Antibiotics are a risk factor for IBS in asymptomatic individuals. Possible mechanisms should be investigated in future studies" [13] .…”

Section: Small Intestinal Bacterial Overgrowth and Ibsmentioning

confidence: 99%

Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae

Helo

2019

Journal of Gastroenterology and Hepatology Research

View full text Add to dashboard Cite

AIM: To evaluate the effect of probiotic Saccharomyces Cerevisiae in the treatment of Irritable Bowel Syndrome in a randomized, double-blind placebo-controlled clinical trial. METHODS: A randomized, double-blind placebo-controlled clinical trial has been performed in 347 adults, diagnosed with IBS (Rome III criteria). Subjects were randomized to receive 1000 mg BID of Saccharomyces Cerevisiae daily for four-week, product 177, placebo 170. IBS symptoms (abdominal pain/discomfort, bloating/ distension, bowel movement difficulty) and changes in stool frequency and consistency were recorded daily by the patients and assessed weekly by the investigator. RESULT: Improvement of Gastrointestinal symptoms was significantly higher in the product group, compared to the placebo, on (abdominal pain/discomfort, bloating/distension, bowel movement difficulty, with stool modification), p-value < 0.001 in the treated group, and the ratio between groups (130 vs. 47), (73.4% vs. 27.64%). CONCLUSION: Saccharomyces Cerevisiae significantly improves irritable bowel syndrome symptoms and is well tolerated.

show abstract

“…IBS is narrowly defined by recurrent abdominal pain and discomfort associated with altered bowel habits in the absence of an organic origin or other explanation of symptoms 25 . This condition has a pooled global prevalence as high as 11.2% 26 but makes up as much as 60% of functional gastrointestinal disorders in children 27 . In 2016, the Rome Criteria IV was updated to include the following items to make a diagnosis of IBS: abdominal pain at least 4 days/month in the past 2 months with one or more of the following characteristics related to the abdominal pain: (1) relation to defecation, (2) a change in the frequency of stool, and (3) a change in the appearance of stool, as outlined in Table 1 28 .…”

Section: Ibsmentioning

confidence: 99%

“…A meta-analysis by Harper et al (2018) found that multistrain probiotic trials reported finding a clinically significant improvement in the quality of life of patients with IBS 27 . However, a randomized clinical trial with Hod et al (2016) found that an 8-week treatment with probiotics resulted in improved symptoms in women with IBS, but not significant compared to placebo 64 .…”

Section: Management Of Disaccharidase Deficiency In Ibsmentioning

confidence: 99%

The relationship between disaccharidase deficiencies and irritable bowel syndrome in childre - A literature review

Puertolas¹,

Pagan²,

Andino³

et al. 2019

NGL

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder whose etiology is yet to be completely understood. It classically presents with non-specific symptoms such as abdominal pain and diarrhea. There is significant overlap between these symptoms and those observed in patients with disaccharidase deficiencies. Despite the appreciable literature available on the effects of lactase deficiency in IBS, some of which will be reviewed below, deficiencies of the other disaccharidases, such as sucrase, maltase, and isomaltase, are less commonly considered in patients presenting with symptoms resembling IBS. Multiple treatment modalities have been proposed; however, the lack of consistency in treatment, as well as the absence of a more meticulous diagnostic tool, has made both disorders difficult to distinguish. The objective of this review is to evaluate and summarize the current scientific literature on the possible role of disaccharidase deficiencies on the pathophysiology of IBS symptoms and what implications this has for management.

show abstract

The Role of Bacteria, Probiotics and Diet in Irritable Bowel Syndrome

Cited by 69 publications

References 125 publications

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge

Treatment of Irritable Bowel Syndrome with Saccharomyces Cerevisiae

The relationship between disaccharidase deficiencies and irritable bowel syndrome in childre - A literature review

Contact Info

Product

Resources

About